Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:16:12.912Z.
Consensus retrieved: 2026-10-06T10:18:25.183Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:16:12.912Z.
Quote observation: 2026-10-06T16:13:48.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1c5d1a4dd2ed90e95308857a7b7df8ea0860f9bef9a655807fa9e02aea5f37e0
Forward PE Ratio (N/A) = Dated Quote Price ($1.61) / Consensus Forward EPS ($-2.43)
FORWARD PE RATIO
N/A
Cellectar Biosciences, Inc.
Market Cap
$12.86M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Cellectar Biosciences, Inc. (CLRB) | $12.86M | N/A |
| Lantern Pharma Inc. (LTRN)vs › | $12.76M | N/A |
| Passage Bio, Inc. (PASG)vs › | $12.98M | N/A |
| Cytosorbents Corporation (CTSO)vs › | $12.60M | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.56M | N/A |
| Optimi Health Corp. (OPTH)vs › | $13.48M | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.12M | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.72M | N/A |
| IN8bio, Inc. (INAB)vs › | $13.89M | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.89M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.61, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-2.43 | $-2.65 – $-2.14 | 3 | n/m |
| 2027-12-31 | $-1.92 | $-2.16 – $-1.43 | 3 | n/m |
| 2028-12-31 | $-0.56 | $-0.61 – $-0.52 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
